Heron Therapeutics (HRTX) Q3 2026 earnings review
Heron sells its business as drug sales fall and cash shrinks
Heron Therapeutics, a maker of hospital pain and nausea drugs, agreed to sell its business as its revenue shrank. Total revenue fell 8% from a year ago, or 3% by our math excluding Sustol, an older nausea drug taken off the market in September. Gross margin recovered and cost cuts lifted operating profit, but a required debt paydown cut cash nearly in half to $23 million.
| Revenue excluding discontinued Sustol | -3% total revenue $35.3M, -7.8% from a year ago |
|---|---|
| Acute Care revenue | $15.1M +22.5% from a year ago (+43.9% in Q2) |
| Cash and short-term investments | $23.4M down from $42.7M in Q2 |
| Full-year outlook | None withdrawn in August; CorMedix asset sale announced |
⚖️ Verdict: 🔴 Bearish
The story got worse because growth in the hospital pain and nausea drugs slowed sharply and no longer offsets the shrinking cancer-care business. Sales of Zynrelef, its post-surgical pain drug, slipped from last quarter after the company paused its sales-force expansion, leading Heron to sell substantially all of its assets to CorMedix Therapeutics. One bright spot: gross margin returned to 75% as high-cost inventory cleared.
The question now is what the CorMedix asset sale leaves for Heron's stockholders after paying off $126 million in debt, and whether the company can meet its loan rules until the deal closes. If the purchase price clears the debt with room to spare, common holders recover value; if it mostly covers lenders, little remains. The Form 8-K and Form 10-Q filings will settle both points.
🐂 Bull Case
Lower Production Costs Lifted Gross Margin
Earlier this year, Heron said its gross margin would return to the mid-70s after it worked through expensive batches of Cinvanti, its intravenous drug for chemotherapy nausea. Gross margin reached 74.6% this quarter, up 5.8 percentage points from a year ago and up from 69.3% in the second quarter.
Cost of product sales, which is the direct cost of making and packaging the drugs, dropped from 31.2% of revenue a year ago to 25.4% this quarter, by our math. Inventory reserves and write-offs also fell to $0.5 million from $2.2 million a year earlier, so gross profit held steady at $26.3 million even though total sales shrank.
What to watch: inventory write-offs in the annual filing. Because Heron still holds $91.3 million of inventory against slowing sales, a return to higher write-offs would erase this margin gain.
Cost Cuts Boosted Profit Excluding One-offs
After losing a patent ruling in June, the biotechnology company paused its planned sales-force expansion and tightened spending across the business. Total operating expenses fell 8% from a year ago to $28.0 million, even though the quarter included $1.4 million in project-related legal fees.
General and administrative overhead dropped from 36.6% of revenue to 35.0% by our math, while research and development fell from 9.1% to 8.8%. Combined with the higher gross margin, those cuts narrowed the operating loss from $4.1 million to $1.7 million. Profit before interest, taxes, depreciation and one-offs (Adjusted EBITDA) more than doubled to $3.7 million.
What to watch: quarterly operating expenses prior to the closing of the CorMedix asset sale. Further legal and transaction fees will test whether the business can generate cash on its own before the buyer takes over.
🐻 Bear Case
Acute Care Growth Slowed as Zynrelef Cooled
Heron has pitched its Acute Care division — Zynrelef for post-surgical pain and Aponvie for post-surgical nausea — as its growth engine while its older cancer-care drugs shrink. Although Acute Care rose to 42.9% of total sales from 32.3% a year ago by our math, the division's growth rate cut in half.
- Acute Care revenue: $15.1 million, up 22.5% from a year ago after growing 43.9% in the second quarter
- Zynrelef revenue: $10.6 million, up 13.8% from a year ago, down from $11.1 million last quarter
- Aponvie revenue: $4.5 million, up 49.3% from a year ago, compared with 73.6% growth last quarter
Zynrelef shrank 4.1% from the second quarter by our math because Heron paused its second-half sales-force expansion. That sequential drop gained $1.5 million less than the cancer division lost, so hospital growth is no longer fast enough to keep total revenue flat.
What to watch: fourth-quarter Zynrelef sales against last year's record $12.5 million fourth quarter. A year-over-year decline would show that hospital adoption has stalled without extra sales reps.
Cinvanti Kept Shrinking Before Any Generic Launch
Oncology Supportive Care still provides 57.1% of Heron's revenue by our math, almost entirely from Cinvanti, its drug for chemotherapy nausea. Following a June court ruling against Cinvanti's patents, the company faces the risk of generic competition, and the business is already shrinking on branded price pressure.
Cinvanti sales fell 16.6% from a year ago to $20.0 million, a steeper drop than the 9.7% decline in the second quarter. Meanwhile, the company noted that "Commercial sales of SUSTOL® ceased on September 30, 2026", after its older nausea injection brought in just $0.2 million. Even excluding Sustol by our math, total company sales fell 3.3% from a year ago.
What to watch: any generic Cinvanti launch or appeal update in the quarterly filing. A generic entry would cut deeper into the product that still generates most of Heron's cash.
Debt Paydown Cut Cash Nearly in Half
Last quarter, Heron amended its loan agreement after missing revenue and profit targets, forcing it to pay down debt principal and accept monthly financial tests. The third-quarter balance sheet shows the cost of that reset.
Cash, cash equivalents and short-term investments dropped 45.0% from the second quarter to $23.4 million by our math, down from $42.7 million at the end of June. Over the same three months, non-current notes payable fell by $17.1 million to $91.6 million. Even after the paydown, the drugmaker carries $126.0 million in total debt, or more than five times its cash.
What to watch: the liquidity and debt disclosures in the quarterly Form 10-Q filing. That report will show how much cash buffer Heron has above its monthly loan minimums while it waits for the CorMedix sale to close.
Risks this quarter didn't answer
Heron did not hold a conference call this quarter, leaving four standing issues without an update in the earnings release.
- Asset sale terms: the release announces the CorMedix deal without the purchase price, debt treatment or what remains for common stockholders; the Form 8-K filing will show the terms.
- Loan covenant compliance: management previously promised to report covenant compliance every quarter in place of an outlook, but the release only lists covenant compliance as a forward-looking risk; the Form 10-Q will provide the reading.
- Hospital unit demand and Zynrelef prefilled syringe: the release omits ordering accounts, daily unit growth and the 2027 prefilled syringe programme; the filing or proxy statement will show whether those remain on track.
- Nasdaq listing status: the release notes minimum listing requirements as a risk factor without updating the December 2026 compliance deadline.
👓 Other Themes
CorMedix Agrees to Buy Heron's Business
Heron concluded its strategic review by announcing that it "Entered into a definitive agreement under which CorMedix Therapeutics will acquire substantially all of Heron’s assets". The transaction requires approval from Heron's stockholders and customary closing conditions. Because the earnings release gives no purchase price or timetable, the separate Form 8-K filing will determine what the deal leaves after Heron's $126.0 million in debt.
💲 Other KPIs
Inventory rose 30.4% from a year ago by our math and crept up from $90.6 million in the second quarter. The drugmaker holds nearly four times as much inventory as cash, tying up working capital even as total revenue fell 7.8% from a year ago.
Uncollected bills from customers fell 3.2% from the second quarter by our math, down from $89.6 million at the end of June. Compared with a year ago, receivables still grew 7.0% while sales shrank 7.8%, meaning wholesalers are taking longer to pay than they did last year.
The average share count rose 12.1% from a year ago by our math, following last year's August debt refinancing, which issued new stock and convertible notes. Sequential dilution slowed to 0.3% from the second quarter's 190.3 million shares.
❓ Key Questions
What will common stockholders receive from the CorMedix asset sale?
Heron carries $126.0 million in debt and $225.5 million in total liabilities against $230.4 million in book assets. Without the purchase price and debt payoff terms in the earnings release, investors cannot tell how much cash or stock remains for equity holders.
Did Heron meet its reset monthly loan covenants this quarter?
Last quarter, management promised to report cash, spending and covenant compliance every quarter in place of a full-year outlook. The release gives cash and expenses, but says nothing about whether Heron passed its monthly revenue and profit tests.
Why did Zynrelef revenue shrink from the second quarter?
Zynrelef sales dropped from $11.1 million in the second quarter to $10.6 million in the third. Because Heron cancelled its conference call and omitted daily unit demand figures, it is unclear whether hospital usage fell or wholesaler discounts widened.
Why did Heron not issue a new financial outlook?
The company withdrew its full-year targets in August and stated that "The Company is not providing financial guidance at this time". Investors need to know what standalone cash burn Heron expects between now and the closing of the CorMedix deal.